Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
73.01
+3.31 (4.75%)
At close: Apr 17, 2026, 4:00 PM EDT
72.14
-0.87 (-1.19%)
After-hours: Apr 17, 2026, 7:07 PM EDT
Spyre Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Spyre Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $85.08, which forecasts a 16.53% increase in the stock price over the next year. The lowest target is $53 and the highest is $106.
Price Target: $85.08 (+16.53%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Spyre Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 5 | 7 |
| Buy | 2 | 2 | 2 | 3 | 3 | 5 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 8 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy Maintains $64 → $95 | Strong Buy | Maintains | $64 → $95 | +30.12% | Apr 17, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $50 → $90 | Buy | Maintains | $50 → $90 | +23.27% | Apr 14, 2026 |
| Wedbush | Wedbush | Buy Maintains $65 → $80 | Buy | Maintains | $65 → $80 | +9.57% | Apr 14, 2026 |
| Baird | Baird | Buy Maintains $65 → $90 | Buy | Maintains | $65 → $90 | +23.27% | Apr 14, 2026 |
| Raymond James | Raymond James | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +9.57% | Apr 14, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.98
from -1.98
EPS Next Year
-3.19
from -2.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.11 | -1.48 | |||
| Avg | -2.98 | -3.19 | |||
| Low | -3.91 | -4.76 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.